Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma.
作者： Aideen E. Ryan , Michael O’Dwyer , Janusz Krawczyk , Dawn Swan , Mark Gurney
DOI: 10.1097/HS9.0000000000000350
关键词:
摘要: The alkylating agent cyclophosphamide has been used in the treatment of multiple myeloma for over 60 years. At low doses, also significant immunomodulatory activity, which can be to modify immunosuppressive tumor microenvironment order augment responses existing therapies. Immune-mediated therapies are becoming more widespread modern approaches treatment. In this review, we discuss effects on immune system, and how it synergistically with other modalities including agents, monoclonal antibodies cellular
sci-hub.st 参考文章(108)
Boddy Av, Yule Sm, Wyllie R, Cole M, Tasso Mj, Price L, Pearson Ad, Cyclophosphamide Metabolism in Children Cancer Research. ,vol. 55, pp. 803- 809 ,(1995)
John Hilton, Role of Aldehyde Dehydrogenase in Cyclophosphamide-resistant L1210 Leukemia Cancer Research. ,vol. 44, pp. 5156- 5160 ,(1984)
Zhi-Min Yuan, P. B. Smith, C. Fenselau, M. Colvin, R. B. Brundrett, Glutathione conjugation with phosphoramide mustard and cyclophosphamide. A mechanistic study using tandem mass spectrometry. Drug Metabolism and Disposition. ,vol. 19, pp. 625- 629 ,(1991)
Lorenz Höltl, Reinhold Ramoner, Claudia Zelle-Rieser, Hubert Gander, Thomas Putz, Christine Papesh, Walter Nussbaumer, Claudia Falkensammer, Georg Bartsch, Martin Thurnher, Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. Cancer Immunology, Immunotherapy. ,vol. 54, pp. 663- 670 ,(2005) , 10.1007/S00262-004-0629-2
François Ghiringhelli, Cedric Menard, Pierre Emmanuel Puig, Sylvain Ladoire, Stephan Roux, François Martin, Eric Solary, Axel Le Cesne, Laurence Zitvogel, Bruno Chauffert, Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients Cancer Immunology, Immunotherapy. ,vol. 56, pp. 641- 648 ,(2007) , 10.1007/S00262-006-0225-8
Zhi-Chun Ding, David H Munn, Gang Zhou, Chemotherapy-induced myeloid suppressor cells and antitumor immunity: The Janus face of chemotherapy in immunomodulation OncoImmunology. ,vol. 3, ,(2014) , 10.4161/21624011.2014.954471
Kevin R. McIntosh, Mariangela Segre, Diego Segre, Characterization of cyclophosphamide-induced suppressor cells. Immunopharmacology. ,vol. 4, pp. 279- 289 ,(1982) , 10.1016/0162-3109(82)90049-2
John C. Markley, Michel Sadelain, IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell–mediated rejection of systemic lymphoma in immunodeficient mice Blood. ,vol. 115, pp. 3508- 3519 ,(2010) , 10.1182/BLOOD-2009-09-241398
Hyeoung-Joon Kim, Je-Jung Lee, Thanh Nhan Nguyen Pham, Cheol Yi Hong, Jung-Joon Min, Joon-Haeng Rhee, Truc-Anh Thi Nguyen, Byoung Chul Park, Deok-Hwan Yang, Young-Kyu Park, Hyeong-Rok Kim, Ik-Joo Chung, Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist Experimental and Molecular Medicine. ,vol. 42, pp. 407- 419 ,(2010) , 10.3858/EMM.2010.42.6.042
Christian P. Pallasch, Ilya Leskov, Christian J. Braun, Daniela Vorholt, Adam Drake, Yadira M. Soto-Feliciano, Eric H. Bent, Janine Schwamb, Bettina Iliopoulou, Nadine Kutsch, Nico van Rooijen, Lukas P. Frenzel, Clemens M. Wendtner, Lukas Heukamp, Karl Anton Kreuzer, Michael Hallek, Jianzhu Chen, Michael T. Hemann, Sensitizing Protective Tumor Microenvironments to Antibody-Mediated Therapy Cell. ,vol. 156, pp. 590- 602 ,(2014) , 10.1016/J.CELL.2013.12.041